📺 Novo Nordisk and Eli Lilly’s weight loss drugs are swelling their valuations, and give them a lead in a potentially $50 billion market. Yet rivals like Pfizer are not far behind. aimeedonnellan has more. Watch 👉
日本 最新ニュース, 日本 見出し
Similar News:他のニュース ソースから収集した、これに似たニュース記事を読むこともできます。
Big Pharma will muscle in on obesity gold rushNovo Nordisk and Eli Lilly’s weight loss drugs are swelling their valuations, and give them a lead in a potentially $50 bln market. Yet rivals like Pfizer are not far behind, and others can snap up biotechs like Altimmune. An increasingly crowded sector may lead to lower returns.
続きを読む »
Bay Area experts weigh in on Twitter 'amnesty,' how to handle hate speech, misinformationTwitter CEO Elon Musk says next week he's granting 'amnesty' to suspended accounts.
続きを読む »
Congress should weigh funding cut for police not enforcing gun laws: Sen. Chris MurphySen. Chris Murphy told CNN today that it’s time for the Senate to 'have a conversation' about possibly withholding funding from law enforcement in states that don't enforce state and federal gun laws.
続きを読む »
U.S. Supreme Court to weigh Cuomo-era New York corruption casesThe U.S. Supreme Court on Monday will consider a pair of cases that could it harder to pursue public corruption prosecutions - bids by an ex-aide to Democratic former New York Governor Andrew Cuomo and a businessman to reverse bribery and fraud convictions.
続きを読む »
FTX's demise part 4: Bankruptcy experts weigh in on next steps for FTXThe fourth installment of The Scoop’s continued coverage of FTX’s demise examines the legal underpinnings of FTX’s bankruptcy and restructuring process with attorneys Dan Besikof and Mark Shapiro.
続きを読む »
GBP/USD: Large current account deficit to weigh on Sterling – INGGBP/USD fluctuates below 1.2100. Economists at ING expect Sterling to remain under pressure amid prospects of recession. GBP/USD gains will not last
続きを読む »